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Key points
 Exposure to environmental hypoxia, at high altitude or in a chamber, impairs cardiac energetics
and alters mitochondrial function.
 Inorganicnitrate, aubiquitousdietary constituent, improvesmitochondrial efficiency, lowering
the oxygen cost of exercise, whilst elevated circulating nitrogen oxide levels in high-altitude
natives enhances blood flow.
 Here we report that dietary nitrate supplementation prevents hypoxia-induced changes in
cardiac mitochondrial function and energetics, whilst ameliorating oxidative stress, suggesting
improved tissue oxygenation.
 Furthermore, nitrate supplementation suppresses cardiac arginase expression and increases
tissue L-arginine levels under both hypoxic and normoxic conditions, underpinning a novel
mechanism to enhance the availability of nitric oxide.
 Nitrate supplementationmay thus be of benefit to individuals exposed to hypobaric hypoxia at
altitude or in patients with diseases characterised by tissue hypoxia and energetic impairment,
such as heart failure and chronic obstructive pulmonary disease, or in the critically ill.
Abstract Hypoxic exposure is associated with impaired cardiac energetics in humans and altered
mitochondrial function, with suppressed complex I-supported respiration, in rat heart. This
responsemight limit reactive oxygen species generation, but at the cost of impaired electron trans-
port chain (ETC) activity.Dietary nitrate supplementation improvesmitochondrial efficiency and
can promote tissue oxygenation by enhancing blood flow. We therefore hypothesised that ETC
dysfunction, impaired energetics and oxidative damage in the hearts of rats exposed to chronic
hypoxia could be alleviated by sustained administration of a moderate dose of dietary nitrate.
Male Wistar rats (n = 40) were given water supplemented with 0.7 mmol l−1 NaCl (as control)
or 0.7 mmol l−1 NaNO3, elevating plasma nitrate levels by 80%, and were exposed to 13% O2
(hypoxia) or normoxia (n = 10 per group) for 14 days. Respiration rates, ETC protein levels,
mitochondrial density, ATP content and protein carbonylation were measured in cardiac muscle.
Complex I respiration rates and protein levels were 33% lower in hypoxic/NaCl rats compared
with normoxic/NaCl controls. Protein carbonylation was 65% higher in hearts of hypoxic rats
compared with controls, indicating increased oxidative stress, whilst ATP levels were 62% lower.
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Respiration rates, complex I protein and activity, protein carbonylation and ATP levels were all
fully protected in the hearts of nitrate-supplemented hypoxic rats. Both in normoxia and hypo-
xia, dietary nitrate suppressed cardiac arginase expression and activity and markedly elevated
cardiac L-arginine concentrations, unmasking a novel mechanism of action by which nitrate
enhances tissue NO bioavailability. Dietary nitrate therefore alleviates metabolic abnormalities
in the hypoxic heart, improving myocardial energetics.
(Received 2 April 2014; accepted after revision 18 August 2014; first published online 28 August 2014)
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Introduction
Human exposure to sustained hypobaric hypoxia at high
altitude (Holloway et al. 2011b) or normobaric hypoxia
in a chamber (Holloway et al. 2011a) results in impaired
cardiac energetics upon the subject’s return to normoxia.
The underlying mechanisms remain unresolved, but
lowered electron transport chain (ETC) and Krebs
cycle enzyme activities have been reported in the
hypoxic rat heart (Heather et al. 2012), suggesting
altered mitochondrial function. Similarly, sustained high
altitude exposure results in altered human skeletal
muscle energetics (Edwards et al. 2010) associated
with a loss of mitochondrial density (Murray, 2009;
Levett et al. 2012), downregulation of ETC complexes
I (NADH dehydrogenase) and IV (cytochrome c
oxidase; COX) (Levett et al. 2012) and suppressed
mitochondrial respiratory function (Jacobs et al. 2012).
Such metabolic modifications are likely to be mediated by
the hypoxia-inducible factor (HIF) family of transcription
factors, which are stabilised under conditions of low
cellular oxygen (Semenza, 2007) and by reactive oxygen
species (ROS; Guzy & Schumacker, 2006) and act to
suppress oxidative metabolism, decreasing tissue oxygen
demand in line with the decreased oxygen supply.
It is not immediately clear, however, why tissue
oxygenation might fall in humans at high altitude, as,
with appropriate acclimatisation, a robust erythropoietic
response ensures that blood oxygen content remains
constant up to 7000 m above sea level, despite
the fall in barometric pressure and oxyhaemoglobin
saturation (Grocott et al. 2009). It is possible that micro-
circulatory dysfunction restricts local oxygen delivery;
indeed, impaired blood flow through the sublingual
microcirculation has been reported at high altitude
(Martin et al. 2009), and this may in turn reflect a
deficiency of the biological messenger and vasodilator
nitric oxide (NO). In support of this, microcirculatory
blood flow was found to correlate inversely with plasma
levels of nitrite in humans at altitude, suggesting that the
availability of bioactive nitrogen oxides (NOx) influences
human acclimatisation to hypoxia (Levett et al. 2011).
Moreover, Tibetan natives displayed higher forearm blood
flows than lowlanders at high altitude alongside elevated
circulating levels of NOproducts such as nitrate (Erzurum
et al. 2007).
Dietary nitrate supplementation has been shown to
improve mitochondrial efficiency in humans (Larsen
et al. 2010), decreasing the oxygen cost of exercise (Larsen
et al. 2009). Meanwhile nitrite, a product of either NO
oxidation or nitrate reduction, has been found to protect
mitochondriaduring ischaemia/reperfusion, ameliorating
the rise in ROS production and cytochrome c release,
whilst preserving ATP synthesis (Shiva et al. 2007).
Although nitrite may exert NO-like bioactivity in its own
right (Bryan et al. 2005), it has recently been suggested
that the hypoxia-driven reduction of nitrite to NO during
ischaemiamight preserve high-energy phosphate levels via
an interaction with COX that preserves the efficiency of
proton pumping (Clerc et al. 2007).
We postulated that an enhanced systemic availability of
NOx, achieved via sustained administration of a moderate
dose of dietary inorganic nitrate, might improve tissue
oxygenation during chronic exposure to environmental
hypoxia, preventing oxidative stress and mitochondrial
dysfunction and thereby improving cardiac energetics. To
investigate this, we studied rats exposed to atmospheric
hypoxia (13% O2) or normoxia (21% O2) for 2 weeks
and supplemented animals with either 0.7 mmol l−1
NaCl (as control) or 0.7 mmol l−1 NaNO3 in drinking
water. In pilot studies this dose was found to result in
a similar nitrate intake per unit body mass to that pre-
viously shown to alter mitochondrial function in humans
(Larsen et al. 2010) and to elevate plasma nitrogen
oxide levels. Mitochondrial function was assessed in
cardiac muscle fibres alongside ETC protein levels and
mitochondrial density. Protein carbonyls were analysed as
amarker of oxidative stress,whilst high-energyphosphates
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reflected tissue energetics. Additionally, to investigate a
potential mechanism, expression of arginase I and II and
tissue arginase activity were measured in cardiac extracts
alongside the expression of HIF-1 targets to indicate
possible changes in arginine availability/utilisation and
tissue oxygenation status. We found that dietary nitrate
fully prevents the metabolic and energetic perturbations
that arise in themyocardium following sustained exposure
to environmental hypoxia.
Methods
Ethical approval
All experiments conformed toUKHomeOffice guidelines
under the Animals in Scientific Procedures Act and were
reviewed by the University of Cambridge Animal Welfare
and Ethical Review Committee.
Animals
Male Wistar rats (273 ± 2 g; n = 40) were obtained
from a commercial breeder (Charles River, Margate, UK),
pair-housed in conventional cages with a normal 12 h/12 h
light/dark photoperiod and maintained on distilled water
and a standardized quality-controlled rodent chow to
normalise micronutrient levels (RM1(E) SQC, Special
Diets Services, UK). After 12 days, animals received either
0.7 mmol l−1 NaNO3 (nitrate group) or 0.7 mmol l−1
NaCl (control group matched for salinity and sodium
intake; both ultra-pure, Sigma, St Louis, MO, USA) in
distilled water (n= 20 per group); food and water intakes
were measured daily to assess nitrate intakes. After 4 days,
half of each group was transferred to hypoxia chambers
(PFI Systems, Milton Keynes, UK) maintained at 13%
O2 with 20 air changes per hour (n = 10 per group),
whilst the remaining animals were housed in 21% O2. All
animals remained in these atmospheric conditions, with
access to food and NaCl/NaNO3-supplemented water ad
libitum for a further 14 days. After 14 days, animals were
anaesthetised with a 500 mg kg−1 I.P. injection of sodium
pentobarbital (Ve´toquinol, Buckingham, UK). Following
cessation of peripheral nervous function, the chest cavity
was opened and blood samples were drawn from the left
ventricle by cardiac puncture, treated with EDTA and
centrifuged at 5000 g for 5 min at 4°C. The heart was
then immediately excised, rapidly washed in ice-cold PBS,
blotted and weighed. A portion of the left ventricle was
placed in ice-cold biopsy preservation solution (BIOPS;
10 mmol l−1 Ca-EGTA buffer, 0.1 μmol l−1 free calcium,
20mmol l−1 imidazole, 20mmol l−1 taurine, 50mmol l−1
K-Mes, 0.5mmol l−1 dithiothreitol, 6.56mmol l−1 MgCl2,
5.77 mmol l−1 ATP and 15 mmol l−1 phosphocreatine,
pH 7.1) whilst another portion of the left ventricle was
snap-frozen for immunoblotting and metabolite analysis.
Measurement of nitrate, nitrite and
nitroso-compounds
Nitrate and nitrite concentrations in plasma and cardiac
tissue were quantified by ion chromatography using a
dedicatedHPLC system (ENO-20 Analyser, Eicom, Japan)
with sequential on-line reduction of nitrate to nitrite by a
cadmium column and post-column derivatisation with a
modified Griess reagent, as described (Bryan et al. 2004).
Frozen samples were thawed in the presence of 5mmol l−1
N-ethylmaleimide (NEM) and 10 mmol l−1 EDTA, and
tissues homogenised in NEM/EDTA-supplemented PBS
at a dilution factor of 1:6 (w/v). After a further 10 min of
incubation at room temperature samples were vortexed,
deproteinated by addition of ice-cold methanol (1:1,
v/v) and centrifuged. Thereafter, supernatants were sub-
jected to immediate analysis. The concentrations of
total nitroso-compounds (i.e. the sum of S-nitrosothiols
and N-nitrosamines) in plasma were quantified by gas
phase chemiluminescence using the triiodide method, as
described (Bryan et al. 2004).
Respirometry
Cardiac muscle fibre bundles were dissected from fresh
left ventricle in ice-cold BIOPS and incubated with
gentle rocking for 20 min at 4°C in 1.5 ml BIOPS
supplemented with 20 μl of 5 mg mL−1 saponin
to selectively permeabilise the cell membrane, leaving
mitochondrial membranes intact (Kuznetsov et al. 2008).
After permeabilisation, fibres were washed with fresh
respiration medium (0.5 mmol l−1 EGTA, 3 mmol l−1
MgCl2.6H2O, 20mmol l−1 taurine, 10mmol l−1 KH2PO4,
20 mmol l−1 HEPES, 1 g l−1 BSA, 60 mmol l−1
potassium lactobionate, 110 mmol l−1 mannitol and
0.3 mmol l−1 dithiothreitol, adjusted to pH 7.1 with
5 M KOH) three times for 5 min at 4°C with gentle
rocking. For analysis, fibres were added to 500 μl
atmospheric oxygen-equilibrated respiratory medium
maintained at 37°C in a water-jacketed Clark-type
oxygen electrode chamber (Strathkelvin Instruments,
Motherwell, UK). Respiration rates were analysed
by substrate/inhibitor-titration (see inset to Fig. 3),
essentially as described previously (Kuznetsov et al. 2008).
Respiration was first measured in the presence of complex
I substrates (10 mmol l−1 glutamate, 5 mmol l−1 malate),
initially in the absence of ADP (State 2) and thereafter
following the addition of 2 mmol l−1 ADP to stimulate
ATP synthesis (State 3). A respiratory inhibitor was
then added to prevent electron flow from complex I
(0.5 μmol l−1 rotenone), before respiration rates were
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measured in the presence of a complex II substrate
(10 mmol l−1 succinate). In a second assay, respiration
was measured in the presence of palmitoyl-carnitine
(10 mmol l−1) and malate (5 mmol l−1), in the
presence and absence of 2 mmol l−1 ADP. Muscle fibres
were recovered from electrode chambers and dried for
48 h at 80°C, such that respiration rates could later be
normalized to tissue dry mass. Respiratory control ratios
(RCRs), an indicator of the coupling of substrate oxidation
to ADP phosphorylation, were calculated as State 3/
State 2.
Complex I spectrophotometric assay
NADH/ubiquinone oxidoreductase activity wasmeasured
spectrophotometrically in freeze-thawed tissue according
to published protocols (Pon et al. 2007).
Immunoblotting
Protein levels weremeasured inwhole heart homogenates,
using SDS-PAGE and immunoblotting, as described
(Heather et al. 2006). Evenness of protein loading and
quality of transferwere confirmedbyPonceau staining and
homogeneity between gels ensured by loading multiple
control samples on every gel. Bands were quantified
using UN-SCAN-It software (Silk Scientific, Orem, UT,
USA). The Total OXPHOS Detection Kit (Mitosciences,
Eugene, OR, USA) is a five-antibody cocktail which
determines protein levels of the ETC complexes. Anti-
bodies to the 20 kDa subunit of complex I (ND6), the
30 kDa iron–sulphur subunit of complex II (Fe-S), the
core-2 subunit of complex III (47 kDa), Subunit 1 of
complex IV (39 kDa) and the F1α subunit of ATP-synthase
(53 kDa) provide information on levels of these complexes
in their active form, as these subunits are labile when
unassembled. Citrate synthase and PGC-1α protein levels
were detected using antibodies purchased from Abcam
(Cambridge, UK), respectively ab96600 (52 kDa) and
ab54481 (105 kDa).
Detection of protein carbonylation
Protein carbonylation was measured using an OxyBlot
ProteinOxidationDetection Kit (Millipore, Billerica,MA,
USA) according to the manufacturer’s instructions. The
extent of modification of proteins by ROS and other
free radical species was determined after derivatization
of the carbonyl groups with 2,4-dinitrophenylhydrazine.
SDS-PAGE and immunoblotting were then performed
using standard procedures with a primary antibody
against the derivatised carbonyl groups. Evenness of
protein loading and homogeneity between gels were
confirmed using Ponceau staining, as above.
Measurement of adenylates and L-arginine
Metabolites were extracted from heart tissue using an
established water/chloroform/methanol procedure (Le
Belle et al. 2002). To approximately 100 mg crushed
tissue, 600 μl 2:1 methanol/chloroform was added before
processing in a tissue lyser (Qiagen, UK) for 20 min at
25 Hz. After homogenisation, 200 μl water and 200 μl
chloroform were added, before thorough vortexing and
centrifugation at 13,000 g for 15 min. The aqueous
and organic fractions were removed and aliquoted into
separate 2 ml tubes and kept on ice. A further 600 μl
2:1 methanol/chloroform was added to protein pellet
and lysate, and the extraction process repeated as above.
After centrifugation, the two layers were removed, and
combined with the other aqueous and organic fractions
kept on ice, and dried overnight in a stream of nitrogen
under a fume hood.
Adenosine mono-, di- and triphosphate (AMP, ADP
andATP, respectively) and L-arginineweremeasuredusing
hydrophilic interaction liquid chromatography-mass
spectrometry (HILIC-MS). Samples were reconstituted in
70:30 acetonitrile/water and analysed on a Quattro Pre-
mier XE triple quadrupole-mass spectrometer (Waters,
Elstree, UK). Multiple reaction monitoring in positive
ion mode was used with the following optimised mass
transitions: AMP 348.03 > 135.90; ADP 427 > 135.90;
ATP 507.91 > 135.90; L-arginine 231.20 > 70.10. AMP,
ADP, ATP and L-arginine had separately optimised
cone voltages and collision energies: 95.0 V, 18 eV;
30.0 V, 30.0 eV; 30.0 V, 30.0 eV; and 35.0 V, 15.0 eV;
respectively. Other optimisation parameters common to
each species were as follows: capillary voltage 3.5 kV;
source temperature 110°C for adenylates and 150°C
for L-arginine with desolvation temperature of 350°C
for all metabolites. Chromatographic separation was
achieved using a 100 mm × 2.1 mm × 5 μm
ZIC-HILIC column (Sequant, Sweden) with isocratic
70:30 acetonitrile/100 mM ammonium acetate at a flow
rate of 400 μl min−1 for 8 min. Owing to the necessity
of preparing muscle fibres for mitochondrial respiratory
analysis, it was not possible to instantly snap-freeze heart
tissue for mass spectrometry, and hence the levels of
ATP, ADP, AMP and L-arginine are presented as relative
levels rather than true in vivo concentrations, although
the levels are legitimately comparable within and between
experimental groups.
RNA purification
Total RNA was purified from crushed, frozen heart
using an RNeasy Mini Kit (QIAgen, Valencia, CA,
USA) according to the manufacturer’s specifications.
Approximately 25 mg tissue was resuspended in 350 μl
working lysis buffer, before centrifugation at 14,000 g
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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for 3 min in a QIAshredder spin column (QIAgen). The
lysate supernatant was then digested with proteinase K
(QIAgen) for 15 min at 55°C to remove fibrous proteins
thatwouldotherwisedecreaseRNAyield.The solutionwas
centrifuged at 14,000 g for 1min, transferred to a new tube
and 450μl 100%ethanol added.Aftermixing, the solution
was transferred to anRNeasy spin column and centrifuged
at 8000 g for 15 s to bind RNA to the membrane.
Flow-through was discarded and 350 μl wash buffer
added before centrifugation at 8000 g for 15 s to wash
the membrane. To remove DNA from the sample, 80 μl
working DNase I (QIAgen) solution was added directly to
the spin columnmembrane and sampleswere incubated at
room temperature for 15 min. After addition of a further
350 μl wash buffer, the spin column was centrifuged
at 8000 g for 15 s and flow-through was discarded. To
wash the membrane, 500 μl working ethanol buffer was
added before centrifugation at 8000 g for 15 s, after which
flow-through was discarded. A further 500 μl working
ethanol buffer was added before centrifugation at 8000 g
for 2 min. The spin column was placed in a new collection
tube and centrifuged at 14,000 g for 1 min to prevent
carryover of ethanol. To elute pure RNA, 50μl RNase-free
water was added directly to themembrane and the column
placed inanew1.5ml collection tubebefore centrifugation
at 8000 g for 1 min. RNA concentration was quantified
at 260 nm using a SmartSpec Plus spectrophotometer
(Bio-Rad, Hercules, CA, USA).
Reverse transcription and RT-qPCR
Primer annealing was performed in a 10 μl reaction
volume using 1 nmol l−1 dNTPs, 50 ng random hexamers
and 1 μg total RNA, at 65°C for 5 min in a Veriti 96-well
Thermocycler (AppliedBiosystems, FosterCity,CA,USA).
Complimentary DNA was produced from the primer
annealing reaction using 200 U SuperScript III (reverse
transcriptase), 40 U RNaseOUT (recombinant RNase
inhibitor), 20 nmol l−1 dithiothreitol, 20 nmol l−1 MgCl2
and 1× reverse transcriptase buffer (Life Technologies,
Foster City, CA, USA) in a 20 μl final reaction
volume. Thermocycler parameters were as follows: initial
incubation, 10 min at 25°C; cDNA synthesis, 50 min
at 50°C; and reaction termination, 5 min at 85°C. For
analysis of steady-state mRNA levels, relative abundance
of transcripts of interest was assessed by quantitative
PCR in SYBR Green FastStart Universal Master Mix
(Applied Biosystems) with a StepOnePlus detection
system (Applied Biosciences). QuantiTect primer assays
for Vegfa, Pgk1, Slc1a2, Ca9, Nos2, Arg1 and Arg2 were
obtained from QIAgen. Thermocycler parameters were as
follows: initial incubation, 95°C for 10min; with 40 cycles
of both elongation, 15 s at 95°C; and cooling, 1 min at
60°C. Expression levels were normalised to Actb using the
CT method, and subsequently to normoxia/control to
give fold-changes.
Arginase activity
Arginase activity was determined using an arginase
assay kit (Abnova, Taipei City, Taiwan) according to
the manufacturer’s specifications. The method utilises a
chromogen that complexes with urea produced by the
arginase reaction to produce a colour that is directly
proportional to arginase activity in the sample.
Statistics
Results are expressed as means ± SEM. Data were
collated in Excel before one- or two-way ANOVAwas used
to determine significant differences across experimental
groups (Graphpad, Instat). Bonferroni post hoc analysis
allowed for multiple analysis of selected groups where
appropriate. Differences were considered statistically
significant when P 0.05.
Results
Morphology
Neither exposure to environmental hypoxia (13% O2)
nor dietary nitrate supplementation for 2 weeks, alone
or in combination, caused a significant difference in
final body weights or whole heart weights in rats
(Table 1), although trends towards lower body weights
and increased heart weights led to 12% greater heart
weight/body weight ratios in both groups of hypoxic rats
(P  0.01) when compared with normoxic rats. Hypoxic
rats also showed ventricular remodelling, having lower left
ventricle weights and higher right ventricle weights than
their normoxic counterparts, and this was not affected
by dietary nitrate supplementation (Table 1). Lung wet
weight/dry weight ratios were the same in all animals,
and therefore acclimatisation of these rats to hypoxia
did not cause pulmonary oedema. Epididymal fat pad
mass, measured as an index of whole body adiposity,
and tibia length, used as a surrogate measure of body
size, were the same in all animals. No differences in
food or water intake were observed across the treatment
groups.
Nitrate intake and resulting nitrate and nitrite levels
Nitrate intake was calculated from the amount of food
and water consumed each day and measured nitrate
concentrations in both. No differences were observed in
food intake between any of the groups and thus there
was no difference in nitrate intake from food. Due to
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
6 T. Ashmore and others J Physiol 00.0
Table 1. Morphological characteristics
Normoxic Control Normoxic Nitrate Hypoxic Control Hypoxic Nitrate
(n = 10) (n = 10) (n = 9) (n = 9)
Morphological data
Starting body weight (g) 268 ± 5 268 ± 6 276 ± 2 280 ± 4
End body weight (g) 429 ± 8 431 ± 9 416 ± 14 412 ± 12
Heart weight (g) 1.2 ± 0.0 1.3 ± 0.0 1.3 ± 0.0 1.3 ± 0.1
Heart/body mass × 1000 2.85 ± 0.05 2.92 ± 0.05 3.18 ± 0.06∗∗∗ 3.19 ± 0.10∗∗
Left ventricle mass (g) 0.86 ± 0.02 0.84 ± 0.02 0.72 ± 0.03∗∗ 0.77 ± 0.03∗
Right ventricle mass (g) 0.21 ± 0.01 0.22 ± 0.02 0.39 ± 0.02∗∗∗ 0.39 ± 0.02∗∗∗
Epididymal fat pad (g) 3.5 ± 0.3 3.2 ± 0.2 4.4 ± 0.31 3.5 ± 0.34
Tibia length (mm) 47.0 ± 0.2 47.0 ± 0.2 47.0 ± 0.4 47.0 ± 0.4
Lung wet/dry mass 4.70 ± 0.07 4.58 ± 0.08 4.68 ± 0.05 4.71 ± 0.03
Food/water intakes
Food intake (g day−1) 32.1 ± 2.1 32.9 ± 1.3 29.0 ± 0.8 27.1 ± 0.8
Water intake (ml day−1) 51.4 ± 6.0 51.1 ± 2.2 40.9 ± 4.8 35.5 ± 2.5
Rats were housed in normoxia (21% O2) and hypoxia (13% O2) supplemented with either 0.7 mmol l−1 NaCl (Control) or NaNO3
(Nitrate), and corresponding food/water intakes during the treatment phase. ∗P  0.05, ∗∗P  0.01, ∗∗∗P  0.001 vs. normoxic control.
consumption of nitrate-supplemented water, normoxic
nitrate-supplemented animals had a nitrate intake over
seven times greater than normoxic controls (P  0.001),
whilst hypoxic nitrate-supplemented animals had nitrate
intakes over five times greater (P 0.001) than normoxic
controls and six times greater than non-supplemented
hypoxic rats (Fig. 1A).
To determine how nitrate intake altered circulating
nitrite and nitrate levels, their concentrations were
measured in plasma. In normoxic rats, nitrate
Figure 1. Nitrate intake, plasma nitrogen oxide (NOx) levels and cardiac NOx levels
A, total dietary nitrate intake from food and water in normoxic and hypoxic rats with/without nitrate
supplementation. B, plasma levels of nitrate and nitrite. C, cardiac levels of nitrate and nitrite. ∗P 0.05, ∗∗P 0.01,
∗∗∗P  0.001.
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supplementation increased circulating nitrate
concentrations by 80% (P  0.001) compared with
normoxic controls, whilst nitrite concentrations were
unchanged. In hypoxic rats, plasma nitrate levels tended to
be lower than in normoxic counterparts, although this did
not reach statistical significance. In nitrate-supplemented
hypoxic rats, nitrate concentrations were 89% higher
than in non-supplemented hypoxic rats, again, with no
change in nitrite concentration (Fig. 1B).
Next we determined tissue levels of nitrate and its
putative reduction product, nitrite, in the heart. Here,
hypoxia resulted in cardiac nitrate levels that were
around 5- to 7-fold lower than in normoxic controls
(P  0.05; Fig. 1C), and these levels did not change with
nitrate supplementation. Unexpectedly, cardiac nitrate
content was also significantly decreased in the normoxic
nitrate supplementation group compared with controls.
Cardiac nitrite concentrations were not significantly
different across all groups, but tended to be higher in
nitrate-supplemented, normoxic animals compared with
the other three groups.
Cardiac mitochondrial function and protein
expression
Mitochondrial respiration wasmeasured in permeabilised
cardiac muscle fibre bundles using a substrate/inhibitor
titration to indicate the capacity for electron flow through
different complexesof theETC.Complex I-supported state
2 respiration rates (in the presence of glutamate/malate)
were similar in all groups, whilst ADP-stimulated,
state 3 rates were 33% lower (P  0.05) in hypoxic
rats when compared with normoxic controls. Nitrate
supplementation did not alter complex I respiration in
normoxic rats, but restored normal complex I respiration
in the hearts of hypoxic rats (Fig. 2A). RCR (state 3/state
2) was 35% lower in the hearts of hypoxic rats when
compared with those of normoxic controls (Fig. 2B). RCR
wasnot altered bynitrate supplementation in either group,
but was not significantly different from normal levels in
nitrate-supplementedhypoxic rats.Complex II-supported
state 3 rates (succinate/rotenone) were similar across all
groups (Fig. 2A).
Complex I activity levels, measured by a
spectrophotometric assay, were 44% lower in the
hearts of hypoxic rats than in those of normoxic rats
(P  0.05), and were restored to normal levels by nitrate
supplementation (Fig. 2C). Protein expression of complex
I reflected oxygen consumption rates and enzyme activity
levels at this complex, being 33% lower in hypoxic hearts
than in normoxic controls (P  0.05), but restored to
normoxic levels in nitrate-supplemented hypoxic rats.
Cardiac levels of complex IV were lower in hypoxic rats
than in normoxic controls, although this did not reach
significance. Nitrate alone did not alter complex IV
levels, but this was 39% higher in nitrate-supplemented
hypoxic rats compared with non-supplemented hypoxic
rats (P  0.05). Cardiac complex III levels were not
significantly altered across groups, but tended to be
lower in hypoxic than in normoxic rats, and higher in
nitrate-supplemented rats than in non-supplemented
animals. Cardiac levels of complex II and ATP-synthase
(Fig. 2D) were the same in all rats as were levels of citrate
synthase and PGC-1α (Fig. 3A), suggesting no changes
in cardiac mitochondrial density or mitochondrial
biogenesis as a result of either hypoxic exposure or nitrate
supplementation.
Cardiac state 2 respiration rates in the presence of
the more physiological substrate, palmitoyl-carnitine plus
malate, were the same in the hearts of all groups, but
state 3 respiration rates were 43% lower in the hearts of
hypoxic non-supplemented rats compared with normoxic
controls (P 0.001; Fig. 3B). State 3 rates, however, were
the same in the hearts of nitrate-supplemented hypoxic
rats and normoxic controls, whilst nitrate-supplemented
normoxic rat hearts had 25% higher state 3 rates
than normoxic controls (P  0.01; Fig. 3B). With
palmitoyl-carnitine/malate, normoxia/nitrate rats had a
21% higher RCR than normoxic controls (P  0.05),
whilst hypoxia/chloride and hypoxia/nitrate rats had 37%
(P 0.001) and 17% (P 0.05) lower RCRs, respectively,
than normoxic controls (Fig. 3C).
Energetics and oxidative stress
Cardiac ATP levels were 62% lower in hypoxic rats than
in normoxic controls (P  0.001) but were maintained
at normoxic levels in nitrate-supplemented hypoxic rats
(Fig. 4A). ADP levels were 48% lower in the hearts
of hypoxic rats compared with the hearts of normoxic
controls (P  0.001), but were 28% higher in the
hearts of nitrate-supplemented normoxic rats (P  0.05)
and maintained at normoxic levels in the hearts of
nitrate-supplementedhypoxic rats (Fig. 4A).CardiacAMP
levels were unaltered by nitrate supplementation alone,
but were 57% higher (P  0.05) in non-supplemented
hypoxic animals and maintained at normoxic levels
following nitrate supplementation (Fig. 4A).
Nitrate supplementation lowered protein carbonyl
levels in hearts of both normoxic and hypoxic rats.
Compared with normoxic controls, levels of protein
carbonyls were 29% lower in nitrate-supplemented
normoxic rats (P  0.05). Whilst protein carbonyl levels
were 31% higher in non-supplemented hypoxic rats
than normoxic controls (P  0.001), indicating greater
oxidative stress, protein carbonyl content was normal
in nitrate-supplemented hypoxic rats, suggesting that
nitrate supplementation ameliorates the hypoxia-driven
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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increase in cardiac oxidative stress (Fig. 4B). Similarly,
hypoxic exposure resulted in 48% higher total plasma
nitroso-compound levels (although this did not reach
statistical significance), consistent with enhanced systemic
oxidative stress, whilst nitrate supplementation prevented
this (Fig. 4C).
Arginase expression and activity
Expression of the HIF-2 target Arg1was 29% higher in the
hearts of hypoxic rats compared with normoxic/controls
(P  0.05), but was 54% lower in hearts of
nitrate-supplemented normoxic rats (P  0.05) and
71% lower in hearts of nitrate-supplemented hypoxic
Figure 2. Cardiac mitochondrial function, protein levels and enzyme activity
A and B, respiration rates (A) and respiratory control ratio (B) with complex I (glutamate/malate) and complex II
(rotenone/succinate) substrates, acquired in permeabilised cardiac muscle fibres from normoxic and hypoxic rats
with/without nitrate supplementation using a substrate inhibitor titration (see inset, adapted from Cole et al.
2011). C and D, complex I enzyme activity (C) and levels of representative ETC complex subunits (D), in the hearts
of rats. ∗P  0.05, ∗∗P  0.01.
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rats (P  0.01) than in those of normoxic controls
(Fig. 5A). Expression of Arg2, a putative target of both
HIF-1 and HIF-2, followed a similar profile to that of
Arg1, although its expression was not elevated following
2 weeks of hypoxic exposure. Nitrate supplementation,
however, resulted in 41% lower Arg2 expression in the
hearts of nitrate-supplemented normoxic rats (P  0.05)
and 37% lower Arg2 expression in the hearts of
nitrate-supplemented hypoxic rats (P  0.05) compared
with those of normoxic controls (Fig. 5A). Total cardiac
arginase activity reflected these expression patterns, being
51% higher in hypoxic than normoxic rats (P  0.01).
There was no elevation in arginase activity in the hearts
of hypoxic rats when supplemented with nitrate; indeed,
in these hearts activity was 61% lower than in those of
untreated hypoxic rats (P 0.001) and 41% lower than in
those of untreated normoxic controls (P 0.05) (Fig. 5B).
Correspondingly, in the normoxic nitrate-supplemented
Figure 2. Continued
Figure 3. Mitochondrial density and biogenesis markers, and palmitoyl-carnitine respiration
A, levels of citrate synthase and PGC-1α in the hearts of normoxic and hypoxic rats with/without nitrate
supplementation. B and C, respiration rates (B) and respiratory control ratio (C) with palmitoyl-carnitine and
malate substrates in permeabilised cardiac muscle fibres from normoxic and hypoxic rats with/without nitrate
supplementation. ∗P  0.05, ∗∗P  0.01, ∗∗∗P  0.001.
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rats cardiac L-arginine levels were 2.3-fold higher than
in normoxic control rats (P  0.05), whilst L-arginine
levels in the hearts of hypoxic nitrate-supplemented rats
were 3.3-fold higher than in those of hypoxic controls
(P  0.05). Cardiac L-arginine levels were not, however,
altered by hypoxia alone (Fig. 5C). Taken together, these
results indicate that constitutive and hypoxia-induced
arginase activity is amajor factor that limits the availability
of L-arginine for other processes (such as NO production
via NOS) in the heart.
Expression of HIF-1 targets
After 2 weeks of exposure to hypoxia there were no
changes in expression of any HIF-1 targets in the heart.
The expression of the HIF-1 targets Vegfa and Pgk1 were
73% (P  0.01) and 71% lower (P  0.05) in the hearts
of nitrate-supplemented normoxic rats compared with
non-supplemented controls (Fig. 6A), whilst there were
no nitrate-induced changes in the expression of Slc1a2
(Fig. 6A), Ca9 or Nos2 (Fig. 6B). In nitrate-supplemented
hypoxic rats, however, Vegfa was 44% lower (P  0.05;
Fig. 6A), Ca9 54% lower (P  0.05) and Nos2 52%
lower (P  0.01) than in non-supplemented hypoxic rats
(Fig. 6B).
Discussion
Sustained exposure to environmental hypoxia is associated
with altered cardiac energetics (Holloway et al. 2011b)
and mitochondrial function (Heather et al. 2012).
Here we investigated whether a moderate dietary
intake of nitrate, a potential precursor of NO under
hypoxic conditions (Lundberg & Govoni, 2004), can
ameliorate these energetic abnormalities in hypoxic
rats. As expected, hypoxic exposure increased oxidative
stress and caused an energetic impairment in the
heart. Hypoxia elicited a specific loss of complex I
protein levels and enzyme activity in heart mitochondria,
with no changes in either mitochondrial density
or biogenesis, whilst fatty acid oxidation capacity
decreased. Dietary nitrate supplementation enhanced
circulating plasma nitrate levels and fully prevented the
hypoxia-induced loss of complex I, decreased fatty acid
oxidation, impaired energetics and oxidative stress. In
addition, our study hints towards a novel mechanism
by which nitrate administration might enhance NO
bioavailability: via the suppression of tissue arginase
activity, redirecting L-arginine flux from ornithine/urea
production to NO/citrulline formation under both hypo-
xic and normoxic conditions (Fig. 7). Whilst we did not
measure cardiacNOproduction in this study, in a separate
Figure 4. Cardiac energetics and oxidative stress, and plasma nitroso-compounds
A and B, adenosine monophosphate, diphosphate and triphosphate levels (A) and protein carbonyls (B) in the
hearts of normoxic and hypoxic rats with/without nitrate supplementation. C, plasma nitroso-compounds from
the same rats. ∗P  0.05, ∗∗P  0.01, ∗∗∗P  0.001.
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study from our laboratory, which used the same dose of
dietary nitrate in normoxic rats alone, cardiac cGMP levels
were 38%higher in the hearts of the nitrate-supplemented
group (P  0.01; data not shown). cGMP is a marker
of NO bioactivity, secondary to the activation of soluble
guanylate cyclase by NO. This novel action of nitrate may
thus increase the proportion of NO production from
endogenous sources by shifting substrate (L-arginine)
utilisation from arginase to NO-synthase, therefore
preventing mitochondrial dysfunction and combating
oxidative stress. It is possible that the same mechanism
accounts for some of the effects of inorganic nitrate in
humans, including the blood pressure lowering (Webb et
al. 2008) and oxygen-sparing effects (Larsen et al. 2010)
reported by others.
A major strength of our study lies in the tightly
controlled intake of nitrate within experimental groups,
achieved via provision of a quality-controlled diet and
nitrate supplementation via drinking water, with the
matching of salinity and sodium intake in control animals.
Whilst an additional non-NaCl-supplemented control
groupwasnot used, validation studies fromour laboratory
have shown that the dose of NaCl used has no effect
on any of the study outcomes or any other outcome we
have measured. An additional strength is the moderate
dose of nitrate employed. As such, the circulating nitrate
concentrations measured in this study can readily be
achieved in humans via a slight modification of the diet.
NO production rates (Siervo et al. 2011) and circulating
nitrate and nitrite concentrations (Pannala et al. 2003)
are very similar in rats and humans, and indeed the
nitrate dose used in our study matches that used in
human studies (Larsen et al. 2010). In addition, the
study involved the use of a wide range of experimental
techniques to understand the hypoxia and nitrate-induced
changes in tissueoxygenmetabolismandenergetics,whilst
observing an excellent agreement in findings across an
array of platforms. Our study also has some limitations.
Due to technical constraints, we can only present relative
levels of adenosine phosphates here, but the levels are
legitimately comparablewithin and between experimental
groups. Another possible limitation of the current study
relates to the lack of data on changes in cardiac function
and/or haemodynamics in response to hypoxia and nitrate
supplementation. Whilst it is now important to establish
the functional consequences of our findings in rigorously
controlled studies, it would clearly be a mistake to report
here a single measure of cardiovascular function that was
altered by hypoxia but reversed by nitrate, and thereby to
conclude that this was due to the changes we report in
mitochondrial function, rather than a consequence of any
of the other systemic effects of hypoxia and/or nitrate.
Figure 5. Expression and activity of cardiac arginase
Expression of arginase I and arginase II (A), total arginase activity (B) and L-arginine levels (C) in the hearts of
normoxic and hypoxic rats with/without nitrate supplementation. ∗P  0.05, ∗∗P  0.01, ∗∗∗P  0.001.
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The degree of hypoxic exposure experienced by rats
in this study represented an inspired PO2 of 12.1 kPa
(91 mmHg) and is approximately the same as that
experienced at 4000 m above sea level, an altitude at
which millions of people worldwide live and work (West,
2004). Exposure to this level of environmental hypo-
xia for 2 weeks was sufficient to elicit changes in the
expression of HIF target genes in the heart, with the
HIF-2 target (Arg1) showing the greatest upregulation
but no apparent upregulation of HIF-1 targets at this
time point. This might suggest a relatively advanced
state of hypoxic acclimatisation, as HIF-1 stabilization is
thought to dominate during acute exposure whilst HIF-2
is stabilized over longer durations of hypoxia (Koh &
Powis, 2012). Unfortunately, due to the need to prepare
muscle fibre bundles from these hearts, we were unable
to snap-freeze myocardium sufficiently rapidly enough
to accurately measure HIF protein levels. In humans at
high altitude, we have reported altered heart and skeletal
muscle energetics (Edwards et al. 2010; Holloway et al.
2011b), and in skeletal muscle this is associated with a
loss of mitochondrial density (Levett et al. 2012) and
the downregulation of the transcriptional co-activator,
PGC-1α, a master regulator of mitochondrial biogenesis
(Levett et al. 2012). In contrast, in the hypoxic rat heart
we found that there was no loss of citrate synthase or
PGC-1α, which appears to corroborate the findings of one
of our co-authors who reported no difference in the yield
of either interfibrillar or subsarcolemmal mitochondria
when isolated from the hypoxic rat heart (Heather et al.
2012).
Following hypoxic exposure we did, however, find
decreased respiration rates, enzyme activity and protein
levels of ETC complex I in the heart. We have previously
found a loss of complex I protein in human skeletalmuscle
(Levett et al. 2012) after prolonged hypoxia and a loss
of complex I-supported respiration in hypoxic human
fibroblasts (Colleoni et al. 2013), suggesting a specific
effect of hypoxia on this complex. Interestingly, Heather et
al. (2012) reported complex I-related respiratory changes
in the hypoxic rat heart that were confined to the
subsarcolemmal population of mitochondria, perhaps
suggesting that in heart, as in skeletal muscle (Levett
et al. 2012), this subpopulation is more susceptible to
hypoxia-driven impairments. The specific loss of complex
Imight serve to decrease superoxide generation via reverse
electron transport through this complex (Turrens &
Boveris, 1980), but at the cost of decreased ATP synthesis.
Whilst we did not measure ATP synthesis rates directly,
we can infer that the capacity for mitochondrial ATP
synthesis is decreased in these hearts as the decreased
RCRs indicate worsened coupling of oxygen consumption
Figure 6. HIF-1 targets
Relative expression of HIF-1 targets (A: Vegfa, Pgk1 and Slc1a2; B: Ca9, Nos2), in the hearts of normoxic and
hypoxic rats with/without nitrate supplementation. ∗P  0.05, ∗∗P  0.01.
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to ATP synthesis, alongside decreased overall capacity for
oxidation of both complex I substrates and the more
physiological substrate, palmitoyl-carnitine. Thus, the
mitochondrial changes measured here probably underlie
the observed depression in cardiac energetics.
In the hypoxic heart, a moderate dose of dietary
nitrate prevented the loss of complex I, and whilst this
might result from improved tissue oxygenation alone, the
reversible formation of S-nitrosothiols is known to alter
the structure and function of proteins, including complex
I subunits (Clementi et al. 1998; Piantadosi, 2012).
Indeed, reversible nitrosation of complex I is known to
inactivate it in several ways (Galkin&Moncada, 2007) and
during ischaemia/reperfusion this modification is known
to be cardioprotective (Larsen et al. 2012; Chouchani
et al. 2013). Future studies might aim to investigate
whether enhanced NO bioavailability via dietary nitrate
supplementation results in such protective modifications,
although it shouldbenoted that complex I activitywaspre-
served in the hearts of normoxic rats with dietary nitrate
supplementation in our study.
Nitrate supplementation therefore protected cardiac
ATP levels and also prevented the hypoxia-induced
increase in protein carbonyls in heart, but notably
also lowered protein carbonyls in the normoxic heart.
Our findings suggest that nitrate improves myocardial
oxygenation in hypoxia, although it remains unclear
whether this is due to enhanced oxygen delivery
via improvements in blood flow, or local effects to
decrease oxygen utilization, for example by improving
mitochondrial efficiency. Moreover, expression of the
HIF-1 targets Vegfa and Pgk1 was downregulated in the
hearts of nitrate-supplemented normoxic rats, possibly
reflecting the elevated tissue nitrate levels we observed
Figure 7. Representation of the effects
of hypoxia on mitochondrial ATP
synthesis, ROS production and arginase
activity (right)
Possible mechanism by which nitrate
supplementation may elicit observed
effects, resulting in improved redox
homeostasis and ATP production via
inhibition of arginase and increased
bioavailability of NO (right), restoring tissue
PO2 . Variations in arrow thickness under
normoxic and hypoxic conditions (with and
without nitrate supplementation) reflect
differences in relative flux rates through
major L-arginine consuming pathways.
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in these hearts, which may improve tissue oxygenation
even in the absence of an environmental hypoxic
stimulus; however, this raises a further question about the
mechanism by which nitrate might elicit this protective
effect.Nitrate supplementation also prevented the hypoxic
rise in total plasma nitroso-compounds (nitrosothiols and
nitrosamines, products the formation of which is known
to be linked to cellular redox status) (Bryan et al. 2004),
providing further evidence for reduced systemic oxidative
stress following nitrate treatment.
Nitrate is widely believed to be a precursor of NO
under hypoxic conditions via sequential reduction, first to
nitrite and then to NO (Lundberg et al. 2008). The latter
step involves multiple enzyme systems and is potently
inhibited by oxygen (Feelisch et al. 2008), but despite its
conceptual appeal as an NOS-independent route of NO
production it isnot yet clearwhat role, if any, thepurported
nitrate–nitrite–NOreductionpathwayplays inphysiology.
While the mechanism by which nitrate administration
gives rise to NO under normoxic conditions remains
similarly unresolved (Tsikas et al. 2013), our findings
suggest that nitrate improves tissue oxygenation even in
the normoxic heart. A novel observation arising from
our investigation is the suppression of cardiac arginase
expression and activity by nitrate. This action could
conceivably shift L-arginine utilisation away from arginase
(and the production of ornithine and urea) towards
NO synthase to enhance NO bioavailability under both
normoxic and hypoxic conditions, with increased NO
production preventing oxidative stress and the loss of
complex I function (Fig. 7). Of note, tissue arginase is
elevated in hypoxia (Pernow & Jung, 2013), and increased
activity has been reported in numerous cardiovascular
pathologies, including congestive heart failure,myocardial
ischaemia and pulmonary arterial hypertension (Pernow
& Jung, 2013), whilst arginase II over-expression in
the mouse endothelium induces endothelial dysfunction,
hypertension and artherosclerosis (Vaisman et al. 2012).
As arginase appears to exert its effects primarily through
the phenomenon of ‘arginine steal’, arginase inhibition has
beenproposedas a therapeutic strategy in suchpathologies
to enhance NO bioavailability and limit oxidative stress.
Our results suggest that this might be readily achievable
via a moderate dose of dietary nitrate. Whilst the under-
lying mechanism remains incompletely resolved at this
stage, nitrate administration decreases the expression of
both arginase I and II, which are recognised targets of
HIF-2; thus, the possible interaction between nitrate and
the HIF-signalling pathway appears to warrant further
investigation. Surprisingly little is known about the trans-
port of nitrate across cell membranes and how intra- and
extracellular concentrations are sensed and regulated. The
seemingly paradoxical decrease in cardiac nitrate levels
observed on nitrate supplementation under normoxic
conditions suggests that measuring plasma levels alone
may be inadequate to assess bodily NO/nitrate status and
hints at a richer level of regulation than is commonly
assumed. Our results are consistent with the notion that
nitrate may be part of a negative feedback loop that serves
to integrate dietary nitrate intake and NO production
from NOS (where nitrate represents the final oxidation
product). Indeed, a similar feedback mechanism has been
proposed to exist for nitritewhereby lowdoses inhibit end-
othelialNOS to increase bloodpressure (Bryan et al.2005).
Irrespective of themechanistic details, the thought that the
ubiquitous dietary constituent nitrate might contribute to
bodily NO production in humans is intriguing.
The functional consequences of the changes to complex
I expression and activity exerted by hypoxia deserve
further consideration, as indeed do the protective effects
of nitrate. Mice with a cardiac-specific complex I
deficiency were recently shown to have normal cardiac
function in vivo, but a predisposition to accelerated heart
failure upon pressure overload stress or with repeated
pregnancy (Karamanlidis et al. 2013). Thus, whilst
complex I loss might exert protection under short-term
hypoxic conditions or during ischaemia/reperfusion,
the longer-term repercussions of ETC suppression and
energetic impairment might include a predisposition to
cardiac failure; indeed, poor cardiac energetics predicts
mortality in patients with chronic heart failure (Neubauer,
2007).
The finding that nitrate supplementation protects
cardiac mitochondrial function and energetics in
sustained hypoxia sheds further light on the adaptations
of high altitude native populations to life in chronic
environmental hypoxia. Tibetans have elevated circulating
levels of NO products associated with improved blood
flow (Erzurum et al. 2007) and the source of nitrogen
oxides in their case is not dietary. Instead, genomic
studies aiming to elucidate the genetic basis of human
high altitude adaptation have highlighted a region of the
NOS2A gene on chromosome 17 as being distinctive in
both Andeans and Tibetans compared with lowlanders
(Bigham et al. 2009, 2010). NOS2A encodes inducible
nitric oxide synthase (iNOS) and is a vital source of NO.
Little is currently known about the energy metabolism
or cardiac energetics of Tibetans, or whether enhanced
nitrogen oxide availability improves the acclimatisation
of lowland natives to high altitude, but these are likely
to be fruitful avenues for further study. In addition, the
potential of moderate dietary nitrate supplementation
for the treatment of hypoxia-related metabolic diseases
deserves further attention. For instance, heart failure is
characterized by poor cardiac energetics, even in patients
receiving optimal therapy, and the degree of energetic
impairment predicts prognosis (Neubauer, 2007). Myo-
cardial hypoxia (Willam et al. 2006), energetic impairment
(Murray et al. 2006) and mitochondrial dysfunction
(Murray et al. 2007, 2008) are all features of the
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non-necrotic, hypertrophied regions of the chronically
infarcted rat heart, and this model of heart failure
would be an interesting one in which to investigate
the therapeutic and cardioprotective potential of dietary
nitrate. Moreover, arginase levels are increased in the
failing human heart and correlate with severity, whilst
arginase inhibition improves microcirculatory function
in these patients by increasing NO availability (Quitter et
al. 2012). It would be interesting to investigate whether
arginase was similarly protective in the pure hypo-
xia setting. Additionally, chronic obstructive pulmonary
disease (COPD) shares many features with chronic
hypoxic exposure at altitude, including similar patterns
of muscle wasting, weight loss and altered cellular
metabolism (Raguso et al. 2004) characterised by a decline
in skeletal muscle mitochondrial function (Meyer et al.
2013). Meanwhile, in critically ill patients who experience
hypoxaemia and tissue hypoxia, survival is strongly
associated with the early induction of mitochondrial
biogenesis (Carre et al.2010), andnitrate supplementation
might augment this process.
Conclusion
We report hypoxia-induced changes in mitochondrial
function in the rat heart, which might underlie the
metabolic perturbations observed in the hearts of
healthy humans at high altitude. A moderate dose of
dietary nitrate alleviated these abnormalities, preventing
the hypoxia-driven downregulation of mitochondrial
complex I, impaired energetics and oxidative stress,
potentially via inhibition of arginase activity. Our
observation that arginase is suppressed by nitrate, even in
normoxia, holds promise for novel dietary interventions
aimed at improving NO production under a variety of
conditions unrelated to hypoxia.
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